CAJ | 학술논문

结直肠癌（ colorectal carcinoma ， CRC）是世界上发病率和死亡率最高的恶性肿瘤之一。 CRC的侵袭和转移往往是导致治疗失败和死亡的主要原因。既往认为CXCR4是CXCL12的专一受体，最近研究表明，CXCL12还存在着CXCR7这一新受体，这2个受体与CXCL12构成的趋化轴与结直肠癌细胞的增殖、迁移、黏附及肿瘤相关血管生成等密切相关，有可能成为抗肿瘤和抗转移治疗的重要新靶点。
결직장암（ colorectal carcinoma ， CRC）시세계상발병솔화사망솔최고적악성종류지일。 CRC적침습화전이왕왕시도치치료실패화사망적주요원인。기왕인위CXCR4시CXCL12적전일수체，최근연구표명，CXCL12환존재착CXCR7저일신수체，저2개수체여CXCL12구성적추화축여결직장암세포적증식、천이、점부급종류상관혈관생성등밀절상관，유가능성위항종류화항전이치료적중요신파점。
Colorectal carcinoma ( CRC ) is one of the malignant tumors with the highest morbidity and mortality rates in the world.The invasion and metastasis of CRC are the major reasons for treatment failure and death .It was believed that CXCR 4 was the exclusive receptor for CXCL12.However, recent studies have identified CXCR7 as a second receptor for CXCL12.Both chemokine ax-es of CXCL12/CXCR4 and CXCL12/CXCR7 closely correlate with the proliferation , migration, adhesion of tumor cells and the forma-tion of tumor-associated vessels in CRC , which may become new significant targets for anti-cancer and anti-metastatic treatment of CRC.